Your browser doesn't support javascript.
loading
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1.
Vacchelli, Erika; Ma, Yuting; Baracco, Elisa E; Zitvogel, Laurence; Kroemer, Guido.
Affiliation
  • Vacchelli E; Gustave Roussy Cancer Campus, Villejuif, France; INSERM, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
  • Ma Y; Gustave Roussy Cancer Campus, Villejuif, France; INSERM, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Su
  • Baracco EE; Gustave Roussy Cancer Campus, Villejuif, France; INSERM, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France.
  • Zitvogel L; Gustave Roussy Cancer Campus, Villejuif, France; Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France; INSERM, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
  • Kroemer G; Gustave Roussy Cancer Campus, Villejuif, France; INSERM, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Me
Oncoimmunology ; 5(5): e1118600, 2016 May.
Article in En | MEDLINE | ID: mdl-27467929
Several pattern recognition receptors including toll-like receptors and purinergic receptors are implicated in the anticancer immune response elicited by anthracyclines or oxaliplatin. Recently, formyl peptide receptor-1 (FPR1) has been involved in this response as well. FPR1 is required for the correct positioning of dendritic cells (DC) close to dying cancer cells. A genetic defect in FPR1 abrogates cross-presentation of tumor antigens by DC, thereby compromising therapy-elicited immunosurveillance.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2016 Document type: Article Affiliation country: France Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2016 Document type: Article Affiliation country: France Country of publication: United States